PharmAsia News
August 12, 2013
Executive SummaryLupin may have made it, but no other India drug maker has been able so set up business in Japan, the second-largest pharmaceutical market in the world and considered to be worth $90 billion.
Lupin may have made it, but no other India drug maker has been able so set up business in Japan, the second-largest pharmaceutical market in the world and considered to be worth $90 billion. One India drug executive blamed Japan's slowness to switch to generics, staggering along at 50% of drug sales compared with 95% in the U.S. An executive of Lupin, which bought its presence in Japan by acquiring control of Kyowa Pharmaceutical in 2007, said the nation's market makes it difficult to enter at the ground level. Some India drug makers have been successful in forming partnerships with Japan generics makers to build their sales.
Executive SummaryLupin may have made it, but no other India drug maker has been able so set up business in Japan, the second-largest pharmaceutical market in the world and considered to be worth $90 billion.
Lupin may have made it, but no other India drug maker has been able so set up business in Japan, the second-largest pharmaceutical market in the world and considered to be worth $90 billion. One India drug executive blamed Japan's slowness to switch to generics, staggering along at 50% of drug sales compared with 95% in the U.S. An executive of Lupin, which bought its presence in Japan by acquiring control of Kyowa Pharmaceutical in 2007, said the nation's market makes it difficult to enter at the ground level. Some India drug makers have been successful in forming partnerships with Japan generics makers to build their sales.